• Company
• Samsung Bioepis’ Opuviz recommended for approval in Europe
• by Whang, byung-woo Sep 24, 2024 05:46am

• Policy
• Pharmbio releases first generic Revolade with reimb in OCT
• by Lee, Tak-Sun Sep 24, 2024 05:46am

• Company
• Will Wegovy launch in KOR continue the Saxenda syndrome?
• by Moon, sung-ho Sep 24, 2024 05:46am

• Company
• Severe asthma biologic 'Nucala' available in the 'Big 5'
• by Eo, Yun-Ho Sep 24, 2024 05:46am

• Company
• Hugelsets sights on Indonesia with botulinum toxin Letybo
• by 어윤호 Sep 23, 2024 09:40am

• Company
• Why royalties for Yuhan’s Leclaza were reduced $300mil
• by Chon, Seung-Hyun Sep 23, 2024 05:51am

• Company
• Will the high-priced Hemgenix be reimbursed in Korea?
• by Whang, byung-woo Sep 23, 2024 05:50am

• InterView
• "An OTC drug increases lymphedema patient satisfaction"
• by Kim, Jin-Gu Sep 23, 2024 05:50am

• Company
• Will restrictions on oral SMA drug Evrysdi be lifted?
• by Eo, Yun-Ho Sep 23, 2024 05:50am

• Policy
• AZ's bispecific ab 'Rilvegostomig' vs Keytruda trial
• by Lee, Hye-Kyung Sep 20, 2024 05:51am